For the year ending 2025-12-31, ISPC had $5,002,427 increase in cash & cash equivalents over the period. -$4,241,062 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenues from external customers | 1,928,998 |
| Cost of revenue, excluding amortization | 1,713,333 |
| Technology expenses, excluding amortization | 688,942 |
| Sales and marketing expenses | 2,295,501 |
| Supply development expenses | 246,979 |
| Fulfillment expenses | 827,501 |
| Other segment items | 4,907,202 |
| Depreciation & amortization expense | 1,730,902 |
| Interest expense | 1,949 |
| Interest income | 3,748 |
| Interest and penalties on sales tax liability | 7,969 |
| Net loss | -10,487,532 |
| Stock-based compensation expense | 21,266 |
| Bad debt expense | 59,863 |
| Write-off of other intangible assets | 525,145 |
| Write-off of accounts payable | -75,000 |
| Write-off of internally developed software | 1,871,064 |
| Accounts receivable | -1,336,475 |
| Inventory | -45,110 |
| Prepaid expenses and other current assets | -194,325 |
| Operating lease right-of-use asset | 58,817 |
| Accounts payable | 1,240,043 |
| Accrued expenses | -549,544 |
| Deferred revenue | -168,173 |
| Depreciation of property and equipment | 68,474 |
| Amortization of internally developed software | 1,470,873 |
| Amortization of other intangible assets | 191,555 |
| Operating lease liability | -43,369 |
| Write-off of accounts receivable unbilled | 0 |
| Non-cash interest income related to accretion of discount on available-for-sale securities | 0 |
| Loss from sales of available-for-sale securities | 0 |
| Loss on disposal of property and equipment | 0 |
| Accounts receivable unbilled | 0 |
| Security deposit | 0 |
| Net cash used in operating activities | -4,240,608 |
| Purchase of property and equipment | 454 |
| Capitalization of intangible asset under development | 1,000,000 |
| Purchase of leasehold improvements included in operating lease right-of-use asset | 0 |
| Purchase of available-for-sale securities | 0 |
| Proceeds from sales and maturities of available-for-sale securities | 0 |
| Net cash provided by (used in) investing activities | -1,000,454 |
| Proceeds from issuance of common stock in with securities purchase agreement | 3,999,574 |
| Proceeds from issuance of common stock in connection with private placement | 1,749,998 |
| Proceeds from issuance of series c convertible preferred stock in connection with pipe financing | 5,500,000 |
| Payment of offering costs in connection with the issuance of common stock in connection with pre-funded warrants and common shares | 1,006,083 |
| Proceeds from issuance of common stock in connection with at the market offering agreement | 0 |
| Proceeds from pre-funded warrants | 0 |
| Payment of offering costs in connection with the issuance of common stock in connection with at the market offering agreement | 0 |
| Repurchase of common stock purchase warrants exercisable under pipe warrants | 0 |
| Net cash provided by financing activities | 10,243,489 |
| Net increase (decrease) in cash and cash equivalents | 5,002,427 |
| Net increase (decrease) in cash and cash equivalents | 5,002,427 |
| Cash and cash equivalents at beginning of year | 1,878,408 |
| Cash and cash equivalents at end of year | 6,880,835 |
iSpecimen Inc. (ISPC)
iSpecimen Inc. (ISPC)